NCT06362265CompletedPhase 1
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 9 Apr 2024
- Start date
- 10 Oct 2024
- Primary completion date
- 2 Jan 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Type 2 diabetes
- NCT number
- NCT06362265
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 15
- From 10 Oct 2024 to the primary completion date, 2 Jan 2026
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had a significant weight gain or loss of approximately 6% or more within 3 months prior to screening.
- Are receiving or received systemic glucocorticoid therapy
- Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product
Other illness
- Have a history of renal impairment
- Have a history of an active or untreated malignancy
Other
- Have had a severe hypoglycemia in the past 6 months
- Have had a blood transfusion or severe blood loss within last 90 days
Who the study is looking for
- Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months
- Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening
- Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m²)
- Participants are insulin naïve or have been without insulin treatment for at least 3 months prior to screening
Age in the registry: 10 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Healthcare of Atlanta Center for Advanced Pediatrics Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
| Joslin Diabetes Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| UBMD Pediatrics Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
| Cincinnati Children's Hospital Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| Centricity Research Columbus Endocrinology Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
| Children's Hospital Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Lifedoc Research - Lenox Park Drive Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
| NYU Langone Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.